Testimony Before the FDA’s Pulmonary-Allergy Drugs Advisory Committee on Tiotropium (Spiriva Respimat)

View the Presentation as a PDF.

Public Citizen opposes the Food and Drug Administration’s approval of tiotropium (Spiriva Respimat) because the drug (1) offers no unique advantages over the currently available Spiriva HandiHaler; and (2) appears to have a greater risk of fatal myocardial infarction than Spiriva HandiHaler.